NCT02146937撤回2 期
A Phase 2 Study of Bicalutamide Plus Finasteride in Men With MRI Detectable Prostate Nodules Undergoing Active Surveillance
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 撤回
- 试验地点
- 1
- 主要终点
- Negative re-biopsy rate
研究概览
简要总结
This is an open label, single site, single arm Phase II study to evaluate the combination of bicalutamide plus finasteride in men with MRI detectable significant prostate nodules followed on active surveillance.
详细描述
This research is being done to determine the negative re-biopsy rate as determined by MRI/TRUS fusion guided biopsy targeting the dominant nodule site defined by pre-treatment MRI following three months (90 days) of combination bicalutamide plus finasteride.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 100 Years（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Willing and able to provide written informed consent.
- •Age ≥ 18 years
- •Eastern cooperative group (ECOG) performance status ≤2
- •Documented histologically confirmed adenocarcinoma of the prostate (minimum 12 core prostate biopsy completed within 90 days of screening)
- •Very low-risk prostate cancer as defined by:
- •Gleason score ≤ 6
- •PSA density ≤ 0.15 ng/mL/mL
- •PSA < 10 ng/mL
- •Clinical tumor stage T1 (cT1) (i.e., no palpable nodule by digital rectal exam)
- •≤2 prostate cores positive for prostatic adenocarcinoma
- •≤50% of any given core involved by prostatic adenocarcinoma
- •Willing and qualified for active surveillance at Johns Hopkins
- •Presence of at least one MRI significant visible prostate tumor (i.e., ≥5 mm in at least one dimension) that has been biopsy proven to be prostatic adenocarcinoma Note: MRI may occur pre- or post-prostate biopsy. If done post-biopsy, the MRI must not occur <8 weeks post-prostate biopsy.
- •Serum testosterone ≥150 ng/dL
- •Able to swallow the study drugs whole as a tablet
排除标准
- •Prior local therapy to treat prostate cancer (e.g., radical prostatectomy, radiation therapy, brachytherapy)
- •Prior use of bicalutamide
- •Prior use of finasteride within the past year
- •Prior or ongoing systemic therapy for prostate cancer including, but not limited to:
- •Hormonal therapy (e.g., leuprolide, goserelin, triptorelin)
- •CYP-17 inhibitors (e.g., abiraterone, ketoconazole)
- •Antiandrogens (e.g., bicalutamide, flutamide, nilutamide)
- •Second generation antiandrogens (e.g., enzalutamide, ARN-509)
- •Immunotherapy (e.g., sipuleucel-T, ipilimumab)
- •Chemotherapy (e.g., docetaxel, cabazitaxel)
- •Evidence of serious and/or unstable pre-existing medical, psychiatric or other condition (including laboratory abnormalities) that could interfere with patient safety or provision of informed consent to participate in this study.
- •Any psychological, familial, sociological, or geographical condition that could potentially interfere with compliance with the study protocol and follow-up schedule.
- •Abnormal bone marrow function [absolute neutrophil count (ANC)<1500/mm3, platelet count <100,000/mm3, hemoglobin <9 g/dL]
- •Abnormal liver function (bilirubin, AST, ALT ≥ 3 x upper limit of normal)
- •Abnormal kidney function (serum creatinine ≥ 2 x upper limit of normal)
- •Abnormal cardiac function as manifested by NYHA (New York Heart Association) class III or IV heart failure or history of a prior myocardial infarction (MI) within the last five years prior to enrollment in the study.
研究组 & 干预措施
Combination therapy- bicalutamide and finasteride
Experimental
3-month (90-day) course of bicalutamide 50 mg by mouth daily and finasteride 5 mg by mouth daily
干预措施: Bicalutamide plus Finasteride- Combination therapy (Drug)
结局指标
主要结局
Negative re-biopsy rate
时间窗: three months (90 days)
To determine the negative re-biopsy rate as determined by MRI/TRUS fusion guided biopsy targeting the dominant nodule site defined by pre-treatment MRI following three months (90 days) of combination bicalutamide plus finasteride.
次要结局
- Adverse events as assessed by the revised National Cancer Institute Common Toxicity Criteria (NCI CTC), version 4.0 published 14 June 2010.(2 years)
- Quality of life utilizing the FACT-P and SF36 surveys(2 years)
- Rate of exit at 2 years from the active surveillance program at Johns Hopkins due to pathologic upstaging following treatment with bicalutamide plus finasteride.(2 years)
- PSA progression rates and PSA progression free survival (PFS), as defined by the Prostate Cancer Working Group 2 (PCWG2) criteria, at 2 years [Scher et al, 2008].(2 years)
- Rate of radiographic disappearance of MRI detectable prostate cancer following treatment with combination bicalutamide plus finasteride (i.e., decrease in size of the target prostate cancer nodule below 5 mm).(2 years)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Efficacy and Toxicity of Bicalutamide and Dutasteride vs. Standard Care for Prostate Cytoreduction for BrachytherapyLower Urinary Tract SymptomsProstate CancerErectile DysfunctionNCT00866554CHU de Quebec-Universite Laval60
招募中
2 期
A Phase II Trial of Bicalutamide in Patients Receiving Intravesical BCG for Non-muscle Invasive Bladder CancerNon-Muscle Invasive Bladder CancerNCT05327647CHU de Quebec-Universite Laval160
终止
2 期
Bendamustine Plus Brentuximab Vedotin in HL and CD30+ PTCL in First Salvage SettingLymphatic DiseasesNCT02499627Fondazione Italiana Linfomi - ETS43
Unknown
2 期
Bendamustine Plus Subcutaneous Rituximab in Patients With Diffuse Large B-cell LymphomaDiffuse Large B Cell LymphomaNCT02753062Asan Medical Center22
已完成
2 期
Bicalutamide and Ridaforolimus in Men With Prostate Cancer (MK-8669-002)Prostate CancerNCT00777959Merck Sharp & Dohme LLC22